Top 5 Drug Type | Count |
---|---|
Oncolytic virus | 6 |
Gene therapy | 2 |
Therapeutic vaccine | 2 |
Biological products | 1 |
Recombinant vector vaccine | 1 |
Target |
Mechanism PD-1 inhibitors |
Originator Org. |
Active Indication |
Inactive Indication |
Drug Highest PhaseApproved |
First Approval Ctry. / Loc. United States |
First Approval Date04 Sep 2014 |
Target |
Mechanism TYMS inhibitors [+2] |
Active Org. |
Originator Org. |
Active Indication |
Inactive Indication |
Drug Highest PhasePhase 2 |
First Approval Ctry. / Loc.- |
First Approval Date- |
Target- |
Mechanism Immunostimulants |
Active Org. |
Originator Org. |
Active Indication |
Inactive Indication- |
Drug Highest PhasePhase 2 |
First Approval Ctry. / Loc.- |
First Approval Date- |
Start Date05 Apr 2023 |
Sponsor / Collaborator |
Start Date25 Feb 2021 |
Sponsor / Collaborator [+2] |
Start Date17 Jan 2020 |
Sponsor / Collaborator |
Drug(Targets) | Indications | Global Highest Phase |
---|---|---|
T-101 | Hepatitis B More | Phase 2 |
Pembrolizumab ( PD-1 ) | Visible Lesion More | Phase 1/2 |
BT-001(Transgene) ( CSF-2R x CTLA4 ) | Visible Lesion More | Phase 1/2 |
Tipapkinogene sovacivec ( HPV E6 x HPV E7 x MUC1 ) | Human Papillomavirus-Related Vulvar Squamous Cell Carcinoma More | Phase 1/2 |
TG-4050 | Locally Advanced Head and Neck Squamous Cell Carcinoma More | Phase 1/2 |